-
1
-
-
84928761118
-
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
-
(2015)
Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
-
2
-
-
77957273591
-
Improved endpoints for cancer immunotherapy trials
-
Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97.
-
(2010)
J Natl Cancer Inst
, vol.102
, pp. 1388-1397
-
-
Hoos, A.1
Eggermont, A.M.2
Janetzki, S.3
-
3
-
-
84865166929
-
Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer
-
Garon EB. Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer 2012;77:475-81.
-
(2012)
Lung Cancer
, vol.77
, pp. 475-481
-
-
Garon, E.B.1
-
4
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
5
-
-
69949186250
-
Screening for epidermal growth factor receptor mutations in lung cancer
-
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
-
(2009)
N Engl J Med
, vol.361
, pp. 958-967
-
-
Rosell, R.1
Moran, T.2
Queralt, C.3
-
6
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
-
(2013)
N Engl J Med
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
Kim, D.W.2
Nakagawa, K.3
-
7
-
-
84918804764
-
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
-
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
-
(2014)
N Engl J Med
, vol.371
, pp. 2167-2177
-
-
Solomon, B.J.1
Mok, T.2
Kim, D.W.3
-
8
-
-
84903973557
-
Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'
-
Pilotto S, Bonomi M, Massari F, et al. Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. Curr Pharm Des 2014;20:3958-72.
-
(2014)
Curr Pharm Des
, vol.20
, pp. 3958-3972
-
-
Pilotto, S.1
Bonomi, M.2
Massari, F.3
-
9
-
-
84906903314
-
Ramucirumab plus docetaxel versus placebo plus docetaxel for secondline treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL):a multicentre, double-blind, randomised phase 3 trial
-
Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for secondline treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL):a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-73.
-
(2014)
Lancet
, vol.384
, pp. 665-673
-
-
Garon, E.B.1
Ciuleanu, T.E.2
Arrieta, O.3
-
10
-
-
84892967581
-
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled tri. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
-
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled tri. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-55.
-
(2014)
Lancet Oncol
, vol.15
, pp. 143-155
-
-
Reck, M.1
Kaiser, R.2
Mellemgaard, A.3
-
11
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
-
12
-
-
77951473661
-
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
-
Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9.
-
(2010)
Ann Oncol
, vol.21
, pp. 1804-1809
-
-
Reck, M.1
von Pawel, J.2
Zatloukal, P.3
-
13
-
-
84915752188
-
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis
-
Bria E, Massari F, Maines F, et al. Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. Crit Rev Oncol Hematol 2015;93:50-9.
-
(2015)
Crit Rev Oncol Hematol
, vol.93
, pp. 50-59
-
-
Bria, E.1
Massari, F.2
Maines, F.3
-
14
-
-
84914665378
-
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers
-
Ciani O, Davis S, Tappenden P, et al. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care 2014;30:312-24.
-
(2014)
Int J Technol Assess Health Care
, vol.30
, pp. 312-324
-
-
Ciani, O.1
Davis, S.2
Tappenden, P.3
-
15
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
-
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
von Pawel, J.3
-
16
-
-
84936791837
-
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
-
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35.
-
(2015)
N Engl J Med
, vol.373
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
-
17
-
-
84944937210
-
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
-
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39.
-
(2015)
N Engl J Med
, vol.373
, pp. 1627-1639
-
-
Borghaei, H.1
Paz-Ares, L.2
Horn, L.3
-
18
-
-
84942138309
-
Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR)
-
abstr
-
Spira AI, Park K, Mazieres J, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol 2015;33:abstr 8010.
-
(2015)
J Clin Oncol
, vol.33
, pp. 8010
-
-
Spira, A.I.1
Park, K.2
Mazieres, J.3
-
19
-
-
84937513626
-
A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 (PD-1)) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC)
-
abstr
-
Spigel DR, Reckamp KL, Rizvi NA, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 (PD-1)) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:abstr 8009.
-
(2015)
J Clin Oncol
, vol.33
, pp. 8009
-
-
Spigel, D.R.1
Reckamp, K.L.2
Rizvi, N.A.3
-
20
-
-
84935474357
-
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
-
Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015;14:847-56.
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 847-856
-
-
Patel, S.P.1
Kurzrock, R.2
-
21
-
-
84939227614
-
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers
-
Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015;10:e0130142.
-
(2015)
PLoS One
, vol.10
, pp. e0130142
-
-
Carbognin, L.1
Pilotto, S.2
Milella, M.3
-
22
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
-
(2014)
Nature
, vol.515
, pp. 563-567
-
-
Herbst, R.S.1
Soria, J.C.2
Kowanetz, M.3
-
23
-
-
84920956732
-
PD-1 blockade induces responses by inhibiting adaptive immune resistance
-
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
-
(2014)
Nature
, vol.515
, pp. 568-571
-
-
Tumeh, P.C.1
Harview, C.L.2
Yearley, J.H.3
-
24
-
-
84927173508
-
Objective measurement and clinical significance of TILs in non-small cell lung cancer
-
Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 2015;107.
-
(2015)
J Natl Cancer Inst
, pp. 107
-
-
Schalper, K.A.1
Brown, J.2
Carvajal-Hausdorf, D.3
-
25
-
-
85047594488
-
Genetic basis for clinical response to CTLA-4 blockade
-
Snyder A, Wolchok JD, Chan TA. Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med 2015;372:783.
-
(2015)
N Engl J Med
, vol.372
, pp. 783
-
-
Snyder, A.1
Wolchok, J.D.2
Chan, T.A.3
-
26
-
-
84899911233
-
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes
-
Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014;32:1277-80.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1277-1280
-
-
Ellis, L.M.1
Bernstein, D.S.2
Voest, E.E.3
-
27
-
-
84928917822
-
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
-
Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015;33:1889-94.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1889-1894
-
-
Schadendorf, D.1
Hodi, F.S.2
Robert, C.3
-
28
-
-
84929464997
-
Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors
-
Sobrero AF, Pastorino A, Sargent DJ, et al. Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors. Clin Cancer Res 2015;21:1036-43.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1036-1043
-
-
Sobrero, A.F.1
Pastorino, A.2
Sargent, D.J.3
-
29
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
-
(2015)
N Engl J Med
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
-
30
-
-
84939864059
-
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
-
Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015;373:726-36.
-
(2015)
N Engl J Med
, vol.373
, pp. 726-736
-
-
Hyman, D.M.1
Puzanov, I.2
Subbiah, V.3
-
31
-
-
84942240637
-
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
-
Chen TT. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. J Natl Cancer Inst 2015;107.
-
(2015)
J Natl Cancer Inst
, pp. 107
-
-
Chen, T.T.1
|